MMV370
MMV371

Janssen

Product vision
  • Prophylaxis  (TPP-2)
MoA
  • Active moiety is atovaquone (selective inhibitor of cytochrome bc1 complex)
Key features
  • Prodrugs of well tolerated marketed prophylactic drug (atovaquone)
  • High liver-stage potency
Challenges
  • Cost and feasibility of formulation

Status
  • Preclinical development

Next milestone
  • Further formulation work and Good Laboratory Practice (GLP) intra-muscular safety studies
Previously
  • Discovery partnership between MMV and Calibr
  • Names mCBE161, mCKX352
MMV Project Director
  • Dr Andrew Slade